Selective Role of an NH2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion–Independent Prostate Cancer Cells
Open Access
- 15 October 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (20), 10067-10077
- https://doi.org/10.1158/0008-5472.can-07-1267
Abstract
Systemic prostate cancer therapy requires androgen ablation, which inhibits the production or action of androgens. Prostate cancer ultimately relapses during androgen ablation, and an androgen depletion-independent (ADI) phenotype emerges. Aberrant androgen receptor (AR) activation underlies therapy resistance at this stage of the disease, and mounting evidence implicates the large and highly disordered AR NH2-terminal domain (NTD) as a key mediator of this activity. In this study, we investigated the role of the NTD transactivation unit 5 (TAU5) domain in mediating AR transcriptional activity in cell-based models of prostate cancer progression. AR replacement and Gal4-based promoter tethering experiments revealed that AR TAU5 had a dichotomous function, inhibiting ligand-dependent AR activity in androgen-dependent prostate cancer cells, while enhancing ligand-independent AR activity in ADI prostate cancer cells. Molecular dissection of TAU5 showed that a WxxLF motif was fully responsible for its ligand-independent activity. Mechanistically, WxxLF did not rely on an interaction with the AR ligand-binding domain to mediate ligand-independent AR activity. Rather, WxxLF functioned as an autonomous transactivation domain. These data show that ligand-dependent and ligand-independent AR activation rely on fundamentally distinct mechanisms, and define WxxLF as the major transactivation motif within the AR TAU5 domain. [Cancer Res 2007;67(20):10067–77]Keywords
Other Versions
This publication has 42 references indexed in Scilit:
- Ligand-Specific Dynamics of the Androgen Receptor at Its Response Element in Living CellsMolecular and Cellular Biology, 2007
- Androgen receptor decoy molecules block the growth of prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Locus-Wide Chromatin Remodeling and Enhanced Androgen Receptor-Mediated Transcription in Recurrent Prostate Tumor CellsMolecular and Cellular Biology, 2006
- Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer CellsPublished by Elsevier BV ,2006
- The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen ReceptorPublished by Elsevier BV ,2005
- Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid?Cancer Biology & Therapy, 2005
- Recognition and Accommodation at the Androgen Receptor Coactivator Binding InterfacePLoS Biology, 2004
- Characterization of the Two Coactivator-interacting Surfaces of the Androgen Receptor and Their Relative Role in Transcriptional Control*Published by Elsevier BV ,2002
- Delineation of Two Distinct Type 1 Activation Functions in the Androgen Receptor Amino-terminal DomainPublished by Elsevier BV ,1996
- Improvements in protein secondary structure prediction by an enhanced neural networkJournal of Molecular Biology, 1990